

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

ESTABLISHMENT OF JOINT VENTURE COMPANY

This announcement is made pursuant to Rule 17.10 of the GEM Listing Rules.

The Board is pleased to announce that the Company established a joint venture company, 泰州海王生物科技有限公司 (Taizhou Neptunus Bio-technique Company Limited*), with Neptunus Pharmaceutical in Taizhou City, Jiangsu Province, the PRC, on 18 August 2010.

This announcement is made pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”).

Establishment of the JV Company

The board of directors (the “Board”) of Shenzhen Neptunus Interlong Bio-technique Company Limited* (the “Company”) is pleased to announce that the Company established a joint venture company, 泰州海王生物科技有限公司 (Taizhou Neptunus Bio-technique Company Limited*) (the “JV Company”), with 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (“Neptunus Pharmaceutical”) in Taizhou City, Jiangsu Province, the People’s Republic of China (the “PRC”), on 18 August 2010. The JV Company is a domestic limited liability company with a registered capital of RMB1,000,000, of which RMB800,000 was contributed by the Company and RMB200,000 was contributed by Neptunus Pharmaceutical. As at the date of this announcement, all the capital contribution to the JV Company was made. Upon its establishment, the JV Company is owned as to 80% by the Company and 20% by Neptunus Pharmaceutical.

The business scope of the JV Company as set out in its business license is the research and development of biopharmaceutical products. The Company and Neptunus Pharmaceutical established the JV Company with the aim of undertaking research and development of new types of cytokines products (including but not limited to recombinant human thymic peptide α -1 for injection). The Company expects that if any new type of cytokines products is successfully developed by the JV Company and the respective board of directors of the JV Company, the Company and Neptunus Pharmaceutical consider that it is in the commercial interest of the JV

Company to launch such new product to the market, the Company and the JV Company may consider commencing the mass production and sales and marketing of such new product, subject to obtaining all necessary approvals from the relevant government authorities. As at the date of this announcement, no new product has been developed by the JV Company, and the Company and the JV Company do not have any plan for the production and sales and marketing of any new type of cytokines products.

Implications of the GEM Listing Rules

As each of the relevant percentage ratios under Rule 19.07 of the GEM Listing Rules for the establishment of the JV Company is under 5%, the establishment of the JV Company does not constitute a notifiable transaction of the Company under Chapter 19 of the GEM Listing Rules.

Neptunus Pharmaceutical is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited*, a substantial shareholder of the Company, and thus a connected person of the Company. However, as the total capital contribution and commitment of the Company for the establishment of the JV Company is only RMB800,000 (equivalent to approximately HK\$909,091) and each of the relevant percentage ratios relating to the establishment of the JV Company is less than 5%, the establishment of the JV Company is a connected transaction exempt from the reporting, announcement and independent shareholders' approval requirements under Rule 20.31(2) of the GEM Listing Rules.

By order of the Board
**Shenzhen Neptunus Interlong
Bio-technique Company Limited***
Zhang Si Min
Chairman

Shenzhen, the PRC, 26 August 2010

* *For identification purposes only*

Translation of RMB into HK\$ in this announcement is based on the exchange rate of HK\$1 = RMB0.88. Such exchange rate is for the purpose of illustration only and does not constitute a representation that any amount has been, could have been or may be converted at such or any other rates or at all.

As at the date of this announcement, the executive Directors are Mr. Zhang Si Min and Mr. Chai Xiang Dong; the non-executive Directors are Mr. Ren De Quan and Ms. Yu Lin; and the independent non-executive Directors are Mr. Lu Sun, Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "latest company announcement" page for at least 7 days from the day of its posting and on the Company's website at www.interlong.com.